|
Color Blindness, Blue
|
0.740 |
Biomarker
|
disease |
BEFREE |
However, M-CBT treatment did not show significant superiority over standard CBT in the present sample.
|
30346186 |
2018 |
|
Color Blindness, Blue
|
0.740 |
Biomarker
|
disease |
BEFREE |
Some evidence suggests equivalence between tCBT and diagnosis-specific CBT (dxCBT), however more investigations are necessary to clarify any difference in efficacy.
|
27466074 |
2017 |
|
Color Blindness, Blue
|
0.740 |
Biomarker
|
disease |
BEFREE |
Participants were 125 youth, aged 8-17 years, with a primary diagnosis of SAD, who were randomly assigned to generic CBT (CBT-GEN), social anxiety specific CBT (CBT-SAD) or a wait list control (WLC).
|
27988427 |
2017 |
|
Color Blindness, Blue
|
0.740 |
GeneticVariation
|
disease |
UNIPROT |
Substitution of isoleucine for threonine at position 190 of S-opsin causes S-cone-function abnormalities.
|
23022137 |
2012 |
|
Color Blindness, Blue
|
0.740 |
GeneticVariation
|
disease |
UNIPROT |
Human tritanopia associated with two amino acid substitutions in the blue-sensitive opsin.
|
1531728 |
1992 |
|
Color Blindness, Blue
|
0.740 |
GermlineCausalMutation
|
disease |
ORPHANET |
Human tritanopia associated with a third amino acid substitution in the blue-sensitive visual pigment.
|
1386496 |
1992 |
|
Color Blindness, Blue
|
0.740 |
GeneticVariation
|
disease |
UNIPROT |
Human tritanopia associated with a third amino acid substitution in the blue-sensitive visual pigment.
|
1386496 |
1992 |
|
Color Blindness, Blue
|
0.740 |
GermlineCausalMutation
|
disease |
ORPHANET |
Human tritanopia associated with two amino acid substitutions in the blue-sensitive opsin.
|
1531728 |
1992 |
|
Color Blindness, Blue
|
0.740 |
GeneticVariation
|
disease |
BEFREE |
Human tritanopia associated with two amino acid substitutions in the blue-sensitive opsin.
|
1531728 |
1992 |
|
Color Blindness, Blue
|
0.740 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Color Blindness, Blue
|
0.740 |
Biomarker
|
disease |
HPO |
|
|
|
|
Color Blindness, Blue
|
0.740 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Atrial Fibrillation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Paroxysmal atrial fibrillation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Persistent atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
familial atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Mental Depression
|
0.100 |
Biomarker
|
disease |
BEFREE |
One trial (N = 29) found a small benefit of escalating doses of fluoxetine and the treatment of adolescent depression study (TORDIA, N = 334) found significant benefits of combined SSRI or venlafaxine treatment with CBT for most outcomes.
|
31165921 |
2020 |
|
Depressive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
One trial (N = 29) found a small benefit of escalating doses of fluoxetine and the treatment of adolescent depression study (TORDIA, N = 334) found significant benefits of combined SSRI or venlafaxine treatment with CBT for most outcomes.
|
31165921 |
2020 |
|
Depressed mood
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
One trial (N = 29) found a small benefit of escalating doses of fluoxetine and the treatment of adolescent depression study (TORDIA, N = 334) found significant benefits of combined SSRI or venlafaxine treatment with CBT for most outcomes.
|
31165921 |
2020 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development and Initial Psychometrics for a Therapist Competence Instrument for CBT for Youth Anxiety.
|
27929671 |
2019 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Longer GAD duration predicted less anxiety reduction in CBT and ND relative to AR.
|
30714750 |
2019 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this review was therefore to evaluate the effectiveness of digitally delivered psychological therapies (CBT, Attention Bias Modification, Exposure Therapy, Applied Relaxation, Bibliotherapy, Psychodynamic Therapy, Mindfulness, Behavioural Stress Management, Counselling) compared with control conditions and/or other psychological interventions for anxiety disorders (Social Anxiety Disorder (SAD), Health Anxiety, Obsessive-Compulsive Disorder (OCD), Post-traumatic Stress Disorder (PTSD), Specific Phobias, Panic Disorder (PD), Generalised Anxiety Disorder (GAD)].
|
30488330 |
2019 |
|
Anxiety Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Development and Initial Psychometrics for a Therapist Competence Instrument for CBT for Youth Anxiety.
|
27929671 |
2019 |
|
Anxiety Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this review was therefore to evaluate the effectiveness of digitally delivered psychological therapies (CBT, Attention Bias Modification, Exposure Therapy, Applied Relaxation, Bibliotherapy, Psychodynamic Therapy, Mindfulness, Behavioural Stress Management, Counselling) compared with control conditions and/or other psychological interventions for anxiety disorders (Social Anxiety Disorder (SAD), Health Anxiety, Obsessive-Compulsive Disorder (OCD), Post-traumatic Stress Disorder (PTSD), Specific Phobias, Panic Disorder (PD), Generalised Anxiety Disorder (GAD)].
|
30488330 |
2019 |
|
Anxiety Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study examined 72 youth (M<sub>age</sub> = 10.50 years; 45% female; 87.5% non-Hispanic Caucasian) diagnosed with an anxiety disorder and who received family or individual CBT.
|
27355694 |
2019 |